We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Shionogi’s investigative COVID-19 therapy is showing some promise in early laboratory studies, rapidly clearing viral levels and decreasing the period of active shedding, the company reported at the European Congress of Clinical Microbiology and Infectious Diseases. Read More
A large postmarket study suggests that some patients with multiple sclerosis (MS) who are stable on Biogen’s Tysabri (natalizumab) can safely extend their dosing interval from four to six weeks. Read More
Roche’s breast cancer drug candidate giredestrant, an oral selective estrogen receptor degrader (SERD), didn’t meets its primary endpoint of progression-free survival in a phase 2 trial of patients with an advanced form of breast cancer, said the company in an Securities and Exchange Commission (SEC) filing yesterday. Read More
Scynexis said two phase 3 studies of its antifungal drug, ibrexafungerp, showed the drug’s efficacy against difficult-to-treat drug-resistant fungal infections. Read More
The company is seeking approval for the vaccine from the FDA, the European Medicines Agency and the UK’s Medicines and Healthcare products Regulatory Agency. Read More
Evusheld, AstraZeneca’s dual-antibody injection, reduced the risk of COVID-19 by more than 76 percent at three months and by 83 percent at six months after immunization, new trial results show. Read More
Pfizer’s novel antiviral nirmatrelvir plus ritonavir cut the risk of COVID-19-related death or hospitalization by 89 percent relative to placebo, a phase 2/3 study has determined. Read More